Citius Oncology (NASDAQ:CTOR) Trading 9% Higher - What's Next?

Key Points

• Shares of Citius Oncology jumped about 9% intraday to roughly $0.88 (high of $0.92) on Friday, with ~184,627 shares traded, near its average daily volume.
• Analyst sentiment is mixed: the consensus is a Hold with an average target of $6.00 (two Buys, one Sell), while Weiss Ratings reiterated a "sell (e+)" rating.
• The company has a small market cap (~$77.5M), reported negative EPS (−$0.06) and revenue slightly below estimates, and shows high volatility (beta 3.42) with weak liquidity metrics.

Shares of Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) were up 9% during trading on Friday . The company traded as high as $0.92 and last traded at $0.8779. Approximately 184,627 shares changed hands during mid-day trading, an increase of 1% from the average daily volume of 182,982 shares. The stock had previously closed at $0.8052.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Citius Oncology in a research note on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Citius Oncology presently has a consensus rating of "Hold" and an average target price of $6.00.

Citius Oncology Stock Performance

The company has a debt-to-equity ratio of 0.07, a current ratio of 0.83 and a quick ratio of 0.32. The stock has a 50-day moving average price of $0.88 and a 200-day moving average price of $1.18. The company has a market capitalization of $77.50 million, a price-to-earnings ratio of -2.83 and a beta of 3.42.

Citius Oncology (NASDAQ:CTOR - Get Free Report) last posted its earnings results on Friday, February 13th. The company reported ($0.06) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.06). The business had revenue of $3.94 million for the quarter, compared to analyst estimates of $4.37 million.

Hedge Funds Weigh In On Citius Oncology

Large investors have recently modified their holdings of the stock. Citadel Advisors LLC bought a new stake in shares of Citius Oncology during the 3rd quarter worth about $36,000. Bank of America Corp DE lifted its position in Citius Oncology by 5,256.9% during the second quarter. Bank of America Corp DE now owns 8,571 shares of the company's stock worth $37,000 after acquiring an additional 8,411 shares during the last quarter. IFP Advisors Inc lifted its position in Citius Oncology by 49.5% during the third quarter. IFP Advisors Inc now owns 33,215 shares of the company's stock worth $67,000 after acquiring an additional 11,000 shares during the last quarter. OMERS ADMINISTRATION Corp bought a new stake in shares of Citius Oncology during the fourth quarter worth approximately $104,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Citius Oncology by 31.6% during the fourth quarter. Geode Capital Management LLC now owns 220,047 shares of the company's stock worth $220,000 after acquiring an additional 52,875 shares during the period. 70.52% of the stock is owned by institutional investors.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.